When first-line care for plantar heel pain has not worked, the orthobiologic options discussed at Regen.MD are physician-directed platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and micro-fragmented adipose tissue (Lipogems). None of them is a first step, and none of them is offered as a standard package. They are considered only after the diagnosis has been re-confirmed and the current plan has genuinely stopped producing change.
Plantar fasciopathy is the most common reason for plantar heel pain and one of the most prevalent musculoskeletal conditions, with a reported lifetime incidence of 10% in the general population. It is normally considered self-limiting, but when symptoms persist they often last for several months or years [2]. A long history is therefore common among the people asking this question, not unusual.
First, confirm the diagnosis and define what “failed” means
Persistent heel pain deserves a fresh review, not a faster escalation
Escalating to an injection is only sensible if the label on the problem is still correct. The published framework for this condition bases diagnosis on a detailed history, physical examination including palpation, the windlass test and the heel squeeze test, and selective imaging with X-ray, ultrasound or MRI, used specifically to rule out other causes such as tarsal tunnel syndrome or a calcaneal stress fracture [1].
We treat that re-confirmation as the first task, not a formality. Heel pain that has not responded to a reasonable course of care is exactly the population in which a second look at the diagnosis pays off.
What a Clinical Evaluation covers
Entry to Regen.MD is a paid, physician-led Clinical Evaluation with Dr. Gurpreet Singh Padda, MD, MBA, MHP. It reviews your history, your imaging, and the metabolic picture underneath the joint or tendon problem, and it ends with a written plan rather than a same-day procedure.
Part of that conversation is defining what “standard care failed” actually means in your case: what was tried, for how long, at what dose or load, and what changed while you were doing it.
Where orthobiologics sit in a conservative-first pathway
The published sequence puts injectables late
The evidence-based framework for plantar fasciitis sorts thirty treatments into four phases: initial therapies such as rest, ice, compression, elevation, stretching and orthotics; intermediate therapies such as photobiomodulation and extracorporeal shockwave therapy; specialized therapies such as PRP and dry needling; and last-resort surgical therapies reserved for recalcitrant cases. Its stated recommendation is to prioritize low-risk, high-efficacy interventions and progress to invasive treatments only when necessary [1].
That sequence is the same one we use. When someone arrives asking about orthobiologics, the first question is which of the earlier tiers were completed properly and which were abandoned early.
Orthobiologics do not replace the rest of the plan
An injection is a biological input into a tissue that still has to be loaded, unloaded, and rehabilitated. Activity modification, loading progression, and footwear decisions continue after the procedure, and they are usually what determines whether the change holds.
PRP for refractory plantar heel pain
Not all PRP is the same
PRP is the orthobiologic most often asked about for stubborn heel pain, and it does appear in the specialized-therapy tier of the published framework [1]. What that entry does not tell you is which preparation, which concentration, and which tissue target were used, and those differ substantially between clinics.
Leukocyte-poor and leukocyte-rich preparations behave differently, and a tendon or fascial target is not the same problem as an intra-articular one. We match the preparation to the tissue rather than running one protocol for every case.
Why a course of PRP sometimes does not deliver
Some patients do not respond, and a reasonable plan says so in advance. The common reasons are a diagnosis that was not quite right, a target that was not reached, a preparation mismatched to the tissue, or a rehabilitation phase that never happened.
BMAC and micro-fragmented adipose tissue
Autologous options discussed case by case
Bone marrow aspirate concentrate and Lipogems are both autologous: the material comes from you. Both are discussed at Regen.MD within our orthobiologic services as options inside a structured pathway, chosen against your imaging, examination, symptom duration, and response to what you have already tried.
They are not interchangeable with each other or with PRP, and there is no version of this decision that can be made from a search result. It is made from your data.
When surgery is the right conversation
Regen.MD is conservative-first, and surgery is considered only after conservative measures have been exhausted. Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon, so that conversation happens inside the practice rather than as a referral away from it. In the published framework, surgical treatment is likewise reserved for recalcitrant cases [1].
If you also carry knee osteoarthritis, note that we frame PRP for advanced knee arthritis as a bridge therapy prior to joint replacement. It does not rebuild the joint surface, and we do not describe it that way.
Find out what is actually driving your heel pain
Regen.MD begins with a paid, physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Regen.MD, 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport. Call (314) 295-3000 or text (314) 886-5902.
Frequently asked questions
I have had heel pain for over a year. Does that mean the orthobiologic options failed before I started?
No. Plantar fasciopathy is normally considered self-limiting, but persistent symptoms often last for several months or years, so a long history is common rather than disqualifying. What matters is whether the diagnosis still holds and whether the current plan has genuinely stopped producing change. See how we structure a conservative-first plan.
Does PRP always work for plantar heel pain?
No. PRP appears in the specialized-therapy tier of the published treatment framework, not the first tier, and response varies between patients. Preparation, tissue target, and patient selection all differ between protocols, which is part of why some courses of PRP do not deliver what the patient expected. We cover this in detail in why PRP injections fail.
I already had a cortisone shot and it wore off. Does that change what we can consider?
It is useful information rather than a barrier. What a steroid injection did, and for how long, tells us something about the tissue and about what is driving the pain. See why cortisone shots can make heel pain worse.
What about shockwave therapy?
Extracorporeal shockwave therapy sits in the intermediate tier of the published framework, ahead of injectables such as PRP. Where it belongs in your sequence depends on what you have already completed. See our overview of shockwave therapy for chronic tendon pain.
What should I do about pain and anti-inflammatories after an injection?
Ask before you take anything, because post-injection medication guidance is specific to the biologic used and to your own medical history. It is part of the written plan you leave with, not a generic rule. See rest, ice and ibuprofen after PRP for the reasoning we walk patients through.
Sources
- Nweke TC. “Comprehensive Review and Evidence-Based Treatment Framework for Optimizing Plantar Fasciitis Diagnosis and Management.” Cureus, vol. 17, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12294660/ (diagnostic workup; four-phase treatment framework; sequencing of PRP, shockwave and surgery).
- Møller S, Riel H, Wester J, Simony A, Viberg B, Jensen C. “Surgical or non-surgical treatment of plantar fasciopathy (SOFT): study protocol for a randomized controlled trial.” Trials, vol. 23, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9531425/ (reported lifetime incidence of 10%; self-limiting course with symptoms often persisting months to years).